Data-driven analysis generated weekly from 175,000+ drug registrations across 17 African markets.
Analysis of 40 expired drug registrations in Ghana by 2026, revealing key generic entry points in anti-infectives, cardiovascular, and pain management.
AfriReg data reveals 40 new pharma registrations in Rwanda in June 2026, primarily veterinary products. Discover key players and therapeutic trends.
Discover 30 WHO-prequalified medicines with fewer than 3 active registrations in African markets, highlighting significant market access gaps and patient needs.
40 pharmaceutical registrations across five African countries, including essential medicines and key generics, are set to expire by June 2026. This data highlights critical regulatory management needs.
AfriReg's June 2026 roundup reveals key trends in African drug registrations, highlighting market growth, upcoming expiries, and dominant players. Essential insights for regulatory affairs teams.
Analysis of 40 recently expired drug registrations in Ghana by September 2026, revealing high-potential generic entry points for key molecules like Amoxicillin, Ciprofloxacin, and Artemether/Lumefantrine.
Forty new pharmaceutical registrations across Africa in June 2026, predominantly in Egypt, highlight therapeutic trends and key players in the market.
June 2026 roundup of African pharma registrations: 4,000+ new drug approvals, with Nigeria and South Africa leading expiry pipelines. Key market activity and top holders.
AfriReg's May 2026 roundup reveals key trends in African pharma regulation: insights on new registrations, expiry pipeline, and market leaders. Essential for regulatory teams.
Africa's pharma landscape: May 2026 saw significant new drug registrations in South Africa (18,259), Ghana (15,086), and Nigeria (8,775). Key expiries noted for Nigeria. Learn more.
Forty new pharmaceutical products were registered in Nigeria in May 2026. This analysis reveals trends in therapeutic areas and active companies for market players.
Analysis of 40 recently expired market authorizations in Ghana in 2026 reveals potential generic entry points. Focus on therapeutic and market impact.
Forty new pharmaceutical registrations in South Africa in May 2026 signal diverse market activity, with strong generics, oncology, and CNS focus.
Forty new pharmaceutical registrations detected across Africa in May 2026, primarily in Rwanda and Ghana, highlighting key therapeutic areas and market access trends.
Kenya saw 40 new pharmaceutical registrations in May 2026. This AfriReg analysis reveals key trends in therapeutic areas and active companies shaping market access.
40 pharmaceutical registrations, including key generics and essential medicines, are set to expire across Nigeria, Rwanda, Côte d'Ivoire, and South Africa in the next 90 days. We examine the regulatory implications.
Eight active registrations, including essential medicines and food products, are set to expire in Ghana within the next 90 days. Regulatory teams must act swiftly.
Five pharmaceutical registrations are set to expire in South Africa between May and July 2026. This analysis highlights key generics and regulatory implications.
40 pharmaceutical product registrations are set to expire in Nigeria within the next 90 days (May-July 2026). Key products include generics and essential medicines.
AfriReg Pro monitors your portfolio across all 15 markets and alerts you 90 days before expiry.
Start free — no credit card required